As well as considering pharmacological approaches, future screens may also seek genetic modifiers of the phenotype, including knockdown of the Mfn2 paralogue Mfn1, which has been shown in some contexts to compensate for at least some neuropathy-causing mitofusin 2 mutations (Detmer and Chan 2007). Here, MFN1 is linked to neuropathy.